Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Executive Changes Leadership BioPharmaceutical

Executives On The Move: PaxMedica, Aurinia and More

  • News

Executive Summary

Recent executive moves in the industry include C-suite changes at PaxMedica and Amicus Therapeutics. Meanwhile, new directors were appointed at Aurinia Pharmaceutical and Skye Bioscience.

You may also be interested in...



Pipeline Watch: Nine Approvals And Nine Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Executives On The Move: C-Suite Changes At ImmunoGen, Kronos Bio, Verve Therapeutics And More

Recent executive moves in the industry include new CEOs at Rentschler Biopharma, MedinCell and OncoZenge, plus C-suite changes at Hinova Pharmaceuticals and ImmunoGen.

Publisher's Spotlight: Scrip Awards Announces 2023 Finalists

We are delighted to announce the shortlist for the 19th Annual Scrip Awards.

Table

View full table

Topics

Tags:
Executive Changes Leadership BioPharmaceutical
Latest Headlines

Asia Deal Watch: Inventiva Finds Japan/Korea Partner For Phase III NASH Candidate In Hepalys

Italy’s Alfasigma Comes Calling After Intercept’s Cruel Summer

What Verona Needs To Make COPD Drug Ensifentrine A Success

Biopharma’s Must-Know Q4 Catalysts

See All
UsernamePublicRestriction

Register

SC148937

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By